AdvantiGen has discovered and validated a new Immune-Checkpoint (IC) target on T-cell for Immuno-Oncology; a market forecasted to grow to > $ 155 Billion by 2031. AdvantiGen ADVAN-1 monoclonal antibody (mAbs) program has delivered a set of mAbs modulating the interaction between this new IC target and its ligand(s), thus restoring the ability of the T cell to kill the cancer cells; the hallmark of an Immune Checkpoint Inhibitors (ICI). AdvantiGen has also shown that its novel target interacts with many cancer cell types, hinting at clinical relevance of the target in both solid tumors, such as skin, kidney, breast, colorectal, lung and liver cancers as well as blood cancers, such T cell Lymphoma and AML.
Company Details
- Employees
- 6
- Founded
- -
- Address
- 510 Charmany Dr, Madison,wisconsin 53719,united States
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.advantigenbio.com
- Keywords
- Immune Checkpoint Inhibitor (ICI), T-cell, Monoclonal Antibodies, Immuno-Oncology, Inflammation.
- HQ
- Madison, Wisconsin
Advantigen Biosciences Questions
Advantigen Biosciences's website is http://www.advantigenbio.com
Advantigen Biosciences's LinkedIn profile is https://www.linkedin.com/company/advantigenbio
Advantigen Biosciences has
6 employees.
View email and phone details for 6
employees at Advantigen Biosciences.
Advantigen Biosciences's industry is
Biotechnology Research
Advantigen Biosciences's top competitors are
Rojobio,
Seva Therapeutics Inc.,
Voximetry,
Selight, Llc,
Forward Biolabs,
Xlock Biosciences, Inc,
Aavective, Inc.,
Bioforward, Inc.,
Invenra,
Nexcalibur Therapeutics.
Advantigen Biosciences's categories are Biotechnology Research
Advantigen Biosciences's founding year is 2015
